Lonza Delivers Strong 2021 performance with 20% CER Sales Growth
Lonza delivers CHF 5.4 billion sales and 20% CER1 sales growth CHF 1.7 billion CORE EBITDA resulted in a margin of 30.8…
Lonza delivers CHF 5.4 billion sales and 20% CER1 sales growth CHF 1.7 billion CORE EBITDA resulted in a margin of 30.8…
Lonza to acquire Exosomics Service Unit in Siena, Italy to expand development service offering in exosome bioprocessing…
Lonza to acquire and operate Codiak's Lexington, MA (US) facility and become the strategic manufacturing partner for Cod…
Curexsys GmbH, a leader in the emerging field of therapeutic exosomes, today announced the appointment of Christian Ecke…
Future Market Insights presents an in-depth analysis as well as a revised forecast for the global liquid biopsy market i…
Future Market Insights in its recent research report titled “Exosome Diagnostic and Therapeutics Market: Global Industry…
GILUPI GmbH is pleased to announce its participation at the 2018 ISMRC (International Symposium on Minimal Residual Canc…
Future Market Insights presents an in-depth analysis as well as a revised forecast for the global liquid biopsy market i…
Damit sich Krebszellen erfolgreich ausbreiten und vermehren können, müssen sie einen Weg finden, um der körpereigenen Ab…
. - Expanding collaboration to develop FDA-regulated diagnostics based on exosomes to measure gene mutations targeted b…